Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases

• US 6,083,501 A
• Filed: 03/14/1996
• Issued: 07/04/2000
• Est. Priority Date: 06/07/1994
• Status: Expired due to Term

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Toray Industries Incorporated
• Inventors: Ida, Nobuo, Ida, Nobutaka, Naruto, Masanobu, Sato, Yu-ichiro, Kojima, Katsuaki, Kasukawa, Reiji, Miyata, Masayuki
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Bansal, Geetha P.
• Application Number:
  US08/592,341
• Time in Patent Office: 1,573 Days
• Field of Search: 530/388.23, 530/399, 424/283.1, 435/63, 514/573, 549/122, 554/117, 554/118, 554/214, 560/121
• US Class Current: 424/158.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07K 16/248 IL-6

Abstract

A drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation, as well as a model animal of fibrinoid formation or thrombus formation in the lung is disclosed. The drug for preventing and treating diseases caused by fibrinoid formation or thrombus formation in the lung according to the present invention comprises an inhibitor of interleukin 6 as an effective ingredient. The model animal of the diseases caused by fibrinoid formation or thrombus formation in the lung is a rat in which fibrinoid formation or thrombus formation actually occurs by induction with interleukin 6.

Claims

1. A method for treating a disease caused by fibrinoid formation in the lung, which comprises:

administering to a subject having such a disease, an effective amount of an inhibitor of interleukin 6 for preventing or treating said disease.

2. The method of claim 1, wherein said inhibitor of interleukin 6 is an antibody which neutralizes interleukin 6.

3. The method of claim 1, wherein said disease caused by fibrinoid formation is pulmonary heart disease (cor pulmonale).

4. The method of claim 3, wherein said pulmonary heart disease is acute pulmonary heart disease, subacute pulmonary heart disease or chronic pulmonary heart disease.

5. The method according to claim 2, wherein said antibody is a monoclonal antibody.

6. The method of claim 1, wherein said inhibitor reduces or inhibits production of IL-6.

7. The method of claim 1, wherein said inhibitor neutralizes IL-6 activity.

8. The method of claim 1, wherein said inhibitor is PGE₁ or a derivative thereof.

9. The method of claim 8, wherein said inhibitor is PGE₁.

10. The method of claim 1, wherein said inhibitor is PGI₂ or a derivative thereof.

11. The method of claim 10, wherein said inhibitor is PGI₂.

12. The method of claim 1, wherein said inhibitor is beraprost.

13. The method of claim 1, wherein said inhibitor is an immunosuppressive agent.

14. The method of claim 13, wherein said inhibitor is cyclophosphamide.

15. The method of claim 2, wherein said antibody is a polyclonal antibody.

16. The method of claim 2, wherein said antibody is IG61 (FERM BP-2878).

17. The method of claim 1, wherein a dose of administration of said inhibitor is in a range of 0.001 mg to 100 mg per 1 kg of body weight per one day.

18. The method of claim 17, wherein the dose of administration of said inhibitor is in a range of 0.01 mg to 10 mg per 1 kg of body weight per one day.